A region of the insulin receptor important for ligand binding (residues 450-601) is recognized by patients' autoimmune antibodies and inhibitory monoclonal antibodies.
Authors:
- 1 November 1991
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 88 (21) , 9858-9862
Abstract
Chimeric receptors containing different portions of the homologous human insulin receptor, insulin-like growth factor I receptor, and insulin receptor-related receptor were utilized to identify the epitopes recognized by various anti-insulin receptor antibodies. The antibodies studied included 12 monoclonal antibodies to the extracellular domain of the human insulin receptor as well as 15 patients' sera with autoimmune anti-insulin receptor antibodies. All of the patients' sera and all 8 monoclonal antibodies that inhibit insulin binding were found to recognize an epitope contained within residues 450-601 of the alpha subunit of the receptor. In contrast, 2 monoclonal antibodies that do not inhibit insulin binding were found to recognize the cysteine-rich region of the alpha subunit. Chimeric insulin receptors that had residues 450-601 replaced with the homologous residues of the insulin-like growth factor I receptor exhibited a decreased ability to bind insulin. In contrast, insulin-like growth factor I receptors that have had the comparable region replaced with that of the insulin receptor showed no decrease in their ability to bind ligand. These results indicate that residues 450-601 of the insulin receptor are important for insulin binding and include the major site for recognition by inhibitory monoclonal antibodies and patients' autoimmune anti-receptor antibodies.Keywords
This publication has 34 references indexed in Scilit:
- The ligand specificities of the insulin receptor and the insulin-like growth factor I receptor reside in different regions of a common binding site.Proceedings of the National Academy of Sciences, 1991
- Binding properties of chimeric insulin receptors containing the cysteine-rich domain of either the insulin-like growth factor I receptor or the insulin receptor related receptorBiochemistry, 1991
- The regulatory role of known tyrosine autophosphorylation sites of the insulin receptor kinase domain. An assessment by replacement with neutral and negatively charged amino acids.Journal of Biological Chemistry, 1991
- Identification and characterization of the ligand-binding domain of insulin receptor by use of an anti-peptide antiserum against amino acid sequence 241-251 of the .alpha. subunitBiochemistry, 1991
- Substitution of lysine for asparagine at position 15 in the alpha-subunit of the human insulin receptor. A mutation that impairs transport of receptors to the cell surface and decreases the affinity of insulin binding.Journal of Biological Chemistry, 1990
- The cysteine-rich domains of the insulin and insulin-like growth factor I receptors are primary determinants of hormone binding specificity. Evidence from receptor chimeras.Journal of Biological Chemistry, 1990
- Changing the insulin receptor to possess insulin-like growth factor I ligand specificityBiochemistry, 1990
- SUBSTRATE PHOSPHORYLATION CATALYZED BY THE INSULIN-RECEPTOR TYROSINE KINASE - KINETIC CORRELATION TO AUTOPHOSPHORYLATION OF SPECIFIC SITES IN THE BETA-SUBUNIT1989
- Syndromes of Autoimmunity and Hypoglycemia: Autoantibodies Directed Against insulinand Its ReceptorEndocrinology and Metabolism Clinics of North America, 1989
- Antibodies That Impair Insulin Receptor Binding in an Unusual Diabetic Syndrome with Severe Insulin ResistanceScience, 1975